Author

M. H. Hofmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:perturbation response prediction· 2 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

D. Gerlach· 2 shared K. Kostyrko· 2 shared A. A. Machado· 1 shared A. Frank· 1 shared A. Jeschko· 1 shared A. Linke· 1 shared A. Sorokin· 1 shared B. Mair· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Gerlach

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma

B. R. Daley, N. E. Sealover, E. Sheffels, J. M. Hughes, D. Gerlach, M. H. Hofmann, K. Kostyrko, B. Mair, A. Linke, Z. Beckley, A. Frank, C. L. Dalgard, R. L. Kortum

This study shows that SOS1 inhibition with BI-3406 enhances G12C inhibitor efficacy and delays resistance in lung adenocarcinoma by targeting resistance mechanisms and drug-tolerant persister cells.

bioRxiv · Dec 7, 2023 · PreprintCancer Biology

Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance

V. Thatikonda, H. Lu, S. Jurado, K. Kostyrko, C. A. Bristow, K. Bosch, N. Feng, S. Gao, D. Gerlach, M. Gerlach, S. Lieb, A. Jeschko, A. A. Machado, E. D. Marszalek, M. Mahendra, , M. H. Hofmann

This study shows that combining KRASG12C and SOS1 inhibitors improves anti-tumor response and delays resistance in KRASG12C-driven cancers.

bioRxiv · Jan 23, 2023Cancer Biology